
HURA Stock Forecast & Price Target
HURA Analyst Ratings
Bulls say
TuHURA Biosciences is currently valued at $636M using a DCF-based methodology, with a target price of $10 per share. Risks associated with this valuation include potential negative clinical results, delays in pipeline advancement, difficulty obtaining regulatory approvals, competition from other checkpoint inhibitors, and potential dilution in the medium-to-long term. However, as a phase 3 clinical stage company with a diverse portfolio of technologies, TuHURA Biosciences has the potential to overcome these risks and experience significant growth in the future.
Bears say
TuHURA Biosciences is currently facing a number of significant challenges, including a recent decline in stock price, which may be attributed to a lack of positive news and updates on their clinical trials, as well as the high costs associated with their research and development efforts. These challenges may hinder the company's ability to meet their upcoming value inflection points and could lead to delayed or disappointing results, making their stock a risky investment option.
This aggregate rating is based on analysts' research of TuHURA Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
HURA Analyst Forecast & Price Prediction
Start investing in HURA
Order type
Buy in
Order amount
Est. shares
0 shares